Amélie Cransac

1.4k total citations
25 papers, 140 citations indexed

About

Amélie Cransac is a scholar working on Pediatrics, Perinatology and Child Health, Geriatrics and Gerontology and Economics and Econometrics. According to data from OpenAlex, Amélie Cransac has authored 25 papers receiving a total of 140 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pediatrics, Perinatology and Child Health, 5 papers in Geriatrics and Gerontology and 5 papers in Economics and Econometrics. Recurrent topics in Amélie Cransac's work include Pharmaceutical studies and practices (6 papers), Pharmaceutical Practices and Patient Outcomes (5 papers) and Medication Adherence and Compliance (4 papers). Amélie Cransac is often cited by papers focused on Pharmaceutical studies and practices (6 papers), Pharmaceutical Practices and Patient Outcomes (5 papers) and Medication Adherence and Compliance (4 papers). Amélie Cransac collaborates with scholars based in France, United States and Réunion. Amélie Cransac's co-authors include Mathieu Boulin, Jean‐Bernard Gouyon, Denis Caillot, C Sgro, Serge Aho, Marie‐Lorraine Chrétien, Maurice Giroud, Auguste Dargent, Michał Abrahamowicz and Omar Ellouze and has published in prestigious journals such as PLoS ONE, Critical Care Medicine and International Journal of Environmental Research and Public Health.

In The Last Decade

Amélie Cransac

19 papers receiving 139 citations

Peers

Countries citing papers authored by Amélie Cransac

Since Specialization

Citations

This map shows the geographic impact of Amélie Cransac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amélie Cransac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amélie Cransac more than expected).

Fields of papers citing papers by Amélie Cransac

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amélie Cransac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amélie Cransac. The network helps show where Amélie Cransac may publish in the future.

Co-authorship network of co-authors of Amélie Cransac

This figure shows the co-authorship network connecting the top 25 collaborators of Amélie Cransac. A scholar is included among the top collaborators of Amélie Cransac based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amélie Cransac. Amélie Cransac is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immediate versus gradual Tocilizu M ab discontinuAtion in G I ant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial 2025 ·BMJ Open ·Maxime Samson, Isabelle Fournel, Abderrahmane Bourredjem, (unknown), (unknown), Amélie Cransac, (unknown), (unknown), (unknown), (unknown), Jean‐Louis Alberini, H. Devilliers, Bernard Bonnotte	0
2	Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial 2025 ·Critical Care Medicine ·Auguste Dargent, Abderrahmane Bourredjem, Marine Jacquier, Julien Bohé, (unknown), Bruno Lévy, Isabelle Fournel, Amélie Cransac, Julio Badié, Luc Quintin, Jean‐Pierre Quenot	3
3	Patients sous anticancéreux : pratiques et attentes des pharmaciens officinaux 2023 ·Bulletin du Cancer ·(unknown), Mathieu Boulin, Amélie Cransac, (unknown), Christine Peyron	2
4	Systematic review of locking solutions for non‐tunneled hemodialysis catheters 2022 ·Hemodialysis International ·(unknown), Auguste Dargent, Pascal Andreu, (unknown), François Aptel, Marie Labruyère, Marine Jacquier, Amélie Cransac, Jean‐Pierre Quenot	2
5	COVID-19 Lockdown in Patients with Chronic Diseases: A Cross-Sectional Study 2022 ·International Journal of Environmental Research and Public Health ·Mathieu Boulin, Amélie Cransac, Marc Maynadié, (unknown), Catherine Creuzot‐Garcher, Jean‐Christophe Eicher, F. Chagué, (unknown), Guillaume Beltramo, Philippe Bonniaud, Thibault Moreau, (unknown), (unknown), (unknown), Marianne Zeller, Yves Cottin	5
6	Dexmedetomidine to reduce vasopressor resistance in refractory septic shock: Protocol for a double-blind randomized controlled pilot trial (ADRESS Pilot study) 2022 ·Frontiers in Medicine ·Auguste Dargent, Abderrahmane Bourredjem, Laurent Argaud, Bruno Lévy, Isabelle Fournel, Amélie Cransac, Julio Badié, Luc Quintin, Jean‐Pierre Quenot	3
7	Smoking in Patients With Chronic Cardiovascular Disease During COVID-19 Lockdown 2022 ·Frontiers in Cardiovascular Medicine ·F. Chagué, Mathieu Boulin, Jean‐Christophe Eicher, F. Bichât, (unknown), Amélie Cransac, (unknown), Nicolas Danchin, Gabriel Laurent, Yves Cottin, Marianne Zeller	2
8	Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study 2022 ·Lung Cancer ·Florian Slimano, (unknown), Amélie Cransac, Pascal Foucher, (unknown), B. Delclaux, (unknown), B. Mennecier, (unknown), (unknown), Sylvain Dukic, Céline Mongaret, Olivier Bouché, (unknown), (unknown), Maxime Dewolf, Lukshe Kanagaratnam	4
9	Polypharmacy and medication regimen complexity in older patients with hemophilia or von willebrand disease: the M’HEMORRH-AGE study 2022 ·International Journal of Clinical Pharmacy ·(unknown), (unknown), Amélie Cransac, Frédéric Gervais, (unknown), (unknown), (unknown), V. Chamouard	1
10	Activités pharmaceutiques relatives aux essais cliniques de médicaments et dispositifs médicaux réalisées au sein des établissements de santé – guide professionnel 2022 ·HAL (Le Centre pour la Communication Scientifique Directe) ·Audrey Lehmann, Laurent Flet, Hélène Bourgoin, Audrey Castet, (unknown), Amélie Cransac, Sarah Djabarouti, (unknown), (unknown), Corinne Guérin, (unknown), (unknown), Lise Bernard	0
11	Alarming increased rate of smoking and associated lifestyle behaviours in patients with chronic cardiac diseases during COVID-19 pandemic related lockdown 2021 ·Archives of Cardiovascular Diseases Supplements ·F. Chagué, Mathieu Boulin, (unknown), F. Bichât, (unknown), Amélie Cransac, Benoît Trojak, (unknown), Nicolas Danchin, Yves Cottin, Marianne Zeller	5
12	Levosimendan in Venoarterial ECMO Weaning. Rational and Design of a Randomized Double Blind Multicentre Trial 2021 ·ESC Heart Failure ·Omar Ellouze, (unknown), (unknown), Osama Abou‐Arab, Emmanuel Besnier, Mouhamed Djahoum Moussa, Amélie Cransac, (unknown), (unknown), Paul‐Michel Mertès, Bélaïd Bouhemad, Pierre‐Grégoire Guinot	21
13	Safety of ninety-minute daratumumab infusion 2020 ·Journal of Oncology Pharmacy Practice ·(unknown), Mathieu Boulin, (unknown), Amélie Cransac, (unknown), C Pernot, (unknown), Ingrid Lafon, Denis Caillot, (unknown)	13
14	Évaluation des coûts médicamenteux évités grâce aux inclusions des patients atteints d’hémopathie maligne dans les essais cliniques 2020 ·Le Pharmacien Hospitalier et Clinicien ·(unknown), Amélie Cransac, (unknown), Denis Caillot, (unknown)	0
15	Trisodium citrate 4% versus heparin as a catheter lock for non-tunneled hemodialysis catheters in critically ill patients: a multicenter, randomized clinical trial 2019 ·Annals of Intensive Care ·Jean‐Pierre Quenot, Julie Helms, Abderrahmane Bourredjem, Auguste Dargent, Ferhat Meziani, Julio Badié, Gilles Blasco, Gaël Piton, Gilles Capellier, Chaouki Mezher, Jean-Michel Rebibou, (unknown), Thomas Crépin, Saber Davide Barbar, (unknown), Amélie Cransac, Mathieu Boulin, Christine Binquet, (unknown), Rémi Bruyère	20
16	Adherence to immunomodulatory drugs in patients with multiple myeloma 2019 ·PLoS ONE ·Amélie Cransac, Serge Aho, Marie‐Lorraine Chrétien, Maurice Giroud, Denis Caillot, Mathieu Boulin	19
17	<p>A single dose of tramadol in continuous wound analgesia with levobupivacaine does not reduce post-sternotomy pain: a randomized controlled trial</p> 2019 ·Journal of Pain Research ·(unknown), Omar Ellouze, Vivien Berthoud, (unknown), Amélie Cransac, Serge Aho, Olivier Bouchot, Claude Girard, Pierre‐Grégoire Guinot, Bélaïd Bouhemad	7
18	What do adult outpatients included in clinical trials know about the investigational drugs being assessed: A cross-sectional study in France 2019 ·PLoS ONE ·(unknown), Maxime C. Paré, P Benoit, (unknown), (unknown), Vérane Schwiertz, (unknown), Amélie Cransac, Christelle Volteau, Jean‐François Huon, (unknown), (unknown), Corinne Guérin, Laurent Flet	2
19	DI-053 Adherence to immunomodulatory drugs in patients with multiple myeloma 2017 ·Amélie Cransac, (unknown), (unknown), C Pernot, Denis Caillot, Mathieu Boulin	1
20	Prévention des erreurs médicamenteuses en néonatologie : de la prescription à l’administration 2012 ·Archives de Pédiatrie ·Jean‐Bernard Gouyon, Amélie Cransac, C Sgro	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact